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Increasing evidence suggests that islet cell transplantation for
patients with type I diabetes holds great promise for achieving
insulin independence. However, the extreme shortage of
matched organ donors and the necessity for chronic immuno-
suppression hasmade it impossible for this treatment to be used
for the general diabetic population. Recent success in generat-
ing insulin-secreting islet-like cells from human embryonic
stem (ES) cells, in combination with the success in deriving
human ES cell-like induced pluripotent stem (iPS) cells from
human fibroblasts by defined factors, have raised the possibility
that patient-specific insulin-secreting islet-like cells might be
derived from somatic cells through cell fate reprogramming
using defined factors. Here we confirm that human ES-like iPS
cells can be derived from human skin cells by retroviral expres-
sion of OCT4, SOX2, c-MYC, and KLF4. Importantly, using a
serum-free protocol, we successfully generated insulin-produc-
ing islet-like clusters (ILCs) from the iPS cells under feeder-free
conditions. We demonstrate that, like human ES cells, skin
fibroblast-derived iPS cells have the potential to be differenti-
ated into islet-like clusters through definitive and pancreatic
endoderm. The iPS-derived ILCs not only contain C-peptide-
positive and glucagon-positive cells but also release C-peptide
upon glucose stimulation. Thus, our study provides evidence
that insulin-secreting ILCs can be generated from skin fibro-
blasts, raising the possibility that patient-specific iPS cells could
potentially provide a treatment for diabetes in the future.
Diabetes is a life-long disease defined by hyperglycemia.
Although type I diabetes is caused by autoimmune destruction
of the pancreatic endocrine beta cells of the patient, type II
diabetes results from insulin resistance. Although current
treatment for type I diabetes is obliged to rely on insulin injec-
tion, due to the difficulties in adjusting the amounts of insulin
administration to accommodate fluctuations in physiological
conditions, this treatment often results in episodes of hypo- and
hyperglycemia. Even under strictly controlled conditions, such
treatment delays but does not always prevent development of
multiple complications including microvascular disease, dia-
betic retinopathy, nephropathy, and neuropathy (1).
Regeneration of insulin-producing beta cell as well as islet
transplantation are the most promising long term solutions for
diabetes treatment (1). For example, clinical trials with islet cell
transplantation from cadaver donors have resulted in promis-
ing outcomes (2–4). Insulin independence with good glycemic
control was achieved and sustained in some patients for more
than 2 years. Although promising, this approach faces multiple
challenges. A major obstacle is the shortage of donors when
compared with the large patient population. In addition,
because the low yield of islet cells from cadaver tissue, it
requires large number of donor cells to generate sufficient insu-
lin-producing beta cells that are capable of producing and
releasing adequate amounts of insulin in response to normal
physiological signals (2–4). Furthermore, chronic immunosup-
pression is necessary after allograft transplantation. These fac-
tors have made it impossible for this treatment to be used for
the general diabetic population.
Although the recurring autoimmune response has to be pre-
vented to avoid destruction of the transplanted cells, derivation
of patient-specific islet-like cells from adult tissues may allow
both shortage of organ donors and allograft rejection to be
resolved. However, generation of functional islet-like clusters
(ILCs)4 from adult progenitor cells including pancreatic pro-
genitor cells has been tested with limited success (5–7). When
compared with adult progenitor cells, human ES cells remain
the most promising source for ILC generation due to their
unlimited replicative capacity and differentiation potentials.
Recent studies have proved that human ES cells can be differ-
entiated into functional islet-like clusters using an in vitro dif-
ferentiation protocol, although the efficiency is relatively low
(8). In addition, transplantation of pancreatic endoderm
derived from human ES cells in vitro can rescue mice with
induced insulin deficiency (9). However, the application of
human ES cell-derived ILC was largely restricted by generation
of patient specific ES cells. Recent demonstrations that human
ES cell-like induced pluripotent stem (iPS) cells can be gener-
ated from adult human somatic cells by enforced expression of
defined transcription factors (10–14) have raised the possibility
that genetically matched insulin-secreting ILCs can be derived
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from somatic cells through differentiation of patient-specific
iPS cells.
Here we confirm that human ES-like iPS cells can be derived
from skin cells by retroviral expression of OCT4, SOX2,
c-MYC, andKLF4. Importantly, using a serum-free in vitropro-
tocol, we successfully generated insulin-producing ILCs from
the iPS cells. Our studies thus raise the possibility that patient-
specific iPS cells could potentially provide an alternative source
for drug screen, study for disease mechanisms, and cell therapy
for diabetes in the future.
EXPERIMENTAL PROCEDURES
Plasmid Construction and Retroviruses Production—The
human Oct4, Sox2, Klf-4, and c-Myc cDNAs were PCR-ampli-
fied from expressed sequence tag clones and cloned into pMXs
at blunted BstXI sites (15). All sequences were confirmed by
DNA sequencing. To generate retroviruses expressing the four
factors, pGag-pol, pVSVG, and pMXs were co-transfected into
293T cells on one 6-well plate at cell density of 8.0  105 cells/
well using SuperFect (Qiagen) according to the manufacturer’s
instructions. Six hours after transfection, the medium was
changed to complete Dulbecco’s modified Eagle’s medium
medium. The viruses were harvest 48 and 72 h after trans-
fection. The harvested viruses were filtered through
0.45-m filter membrane (Millipore) and concentrated by
spin column (Millipore).
Generation and Culture of Human iPS Cells—A total of 8 
105 human foreskin fibroblast HFF-1 cells on one 10-cm plate
were transduced with concentrated retroviruses with Poly-
brene (8 g/ml) two times sequentially. Four days after the
second transduction, 5  104 cells were transferred onto mito-
mycin-C-treated mouse embryonic fibroblast (MEF) feeder
cells. On the second day, the medium was changed to HESM
(Dulbecco’s modified Eagle’s medium/F12 medium (Invitro-
gen) supplemented with 20% knock-out serum replacement
and supplemented with basic fibroblast growth factor (10
ng/ml)). Colonies began to appear 9 days after the second trans-
duction andwere picked based on theirmorphology on days 16,
23, and 30 after transduction. iPS cell lines and the human ES
cell line H9 (WiCell) were maintained as described previously
(WiCell protocols) on mitomycin-treated primary MEF in
HESM (Invitrogen) containing nonessential amino acids, L-glu-
tamine, 2-mercapthoethanol, penicillin-streptomycin, and 10
ng/ml basic fibroblast growth factor (Peprotech) or on
fibronectin (Sigma) using MEF-conditioned HESM. iPS cells
were initially propagated manually and by enzymatic digestion
with collagenase IV (Invitrogen) at later passages.
Immunostaining and TUNEL Assay—iPS cells cultured on
MEFs were fixed with 4% paraformaldehyde overnight at 4 °C,
permeabilized with 0.4% Triton X-100 for 15 min, and blocked
in 1% goat serum in phosphate-buffered saline for 2 h. Cells
were incubatedwith primary antibodies overnight at 4 °C. After
being washed with phosphate-buffered saline, they were incu-
bated with Alexa Fluor (Invitrogen) secondary antibodies and
DAPI for 1 h. SSEA-1, SSEA-4, TRA-1–60, SOX2, and OCT4
antibodies were obtained fromMillipore. Alkaline phosphatase
staining was done according to the manufacturer’s recommen-
dations (Millipore). For immunostaining of differentiated cells,
cell clusters were fixed in 4% paraformaldehyde at room tem-
perature for 30 min, permeabilized in 0.25% Triton X-100, and
blocked with sera/phosphate-buffered saline at room tempera-
ture for 1 h. The cells were incubated with primary antibodies
overnight at 4 °C. The sources of the primary antibodies are:
mouse anti-SOX17 (R&D), goat anti-Foxa2 (R&D), goat anti-
PDX1 (AbCam), mouse anti-C-peptide (AbCam), and rabbit
anti-glucagon (Zymed Laboratories Inc.). Fluorescein isothio-
cyanate- or rhodamine-labeled second antibody was used, and
DAPI or Draq5 were used for nuclear staining. Images were
captured under a fluorescentmicroscope or by confocal micro-
scope (Carl Zeiss). The TUNEL assay of the islet-like clusters
under high glucose was performed using an ApopTag kit
(Chemicon), and the clusters were double-stained with anti-C-
peptide antibody.
Real-time RT-PCR and Bisulfite Sequencing Analysis—Total
RNA fromH9 and iPS cells cultured on fibronectin or under the
differentiation conditions were isolated using the RNeasy kit
(Qiagen). Following DNase I treatment, reverse transcription
was performed using the ImProm-II reverse transcription sys-
tem (Promega). Real-time PCR reactions were performed with
SYBRGreenERmix (Invitrogen) using primer sets listed in sup-
plemental Table 1. Relative gene expression levels were nor-
malized to actin mRNA. Bisulfite sequencing was performed as
described previously with minor modifications (16). Five
micrograms of sodium bisulfite-treated DNA samples was sub-
jected to nested PCR amplification. The PCR products were
subcloned using the TA cloning kit (Invitrogen). All PCR and
subcloning reactions were performed in duplicate for each
sample. The clones were sequenced using an M13 reverse
primer.
Teratoma Formation and Analysis—Teratoma formation
was completed using an Institutional Animal Care and Use
Committee approved protocol. Approximately 2 106 iPS cells
cultured onMEFs were collectedmanually by scrapping, resus-
pended in a mixture of HESM and Matrigel (ratio of 1:1), and
injected subcutaneously into the hind skin flap or intramuscu-
larly into the hind limb of 2–3-month-old immune-compro-
mised Rag2//gamma-C/ mice. Xenografted masses were
observed 4–6 weeks after injection and dissected 6 weeks after
injection. Samples were fixed in 4% paraformaldehyde,
embedded in paraffin, and processed for hematoxylin and
eosin and immunofluorescent staining. The antibodies
against the following proteins were used for immuno-
staining: nestin (BD Biosciences), cytokeratin 19 (AbCam),
-smooth muscle actin (Sigma), and smooth muscle myosin
(Biomedical Technologies).
In Vitro Differentiation of Insulin-secreting Islet-like Clusters—
In vitro differentiation of insulin-secreting islet-like cluster
cells was performed using a protocol described previously with
slight modifications (8). Undifferentiated iPS and hES cells
were cultured in RPMI 1640 supplemented with B27 (Invitro-
gen), 11.1 mM glucose, and 4 nM activin A (Peprotech) for 7
days. Sodium butyrate was added on day 1 at a final concentra-
tion of 0.1 mM (stage 1). After stage 1, the cells were dissociated
with treatment of 1g/ml collagenase IV at 37 °C for 5min and
transferred into ultra-low attachment six-well plates (Corning).
The cell aggregates were cultured in RPMI 1640 supplemented
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with B27, 20 ng/ml epidermal growth factor, 2 ng/ml basic
fibroblast growth factor, and 100 ng/ml noggin (Peprotech) for
2 weeks (stage 2). At stage 3, cell clusters were cultured in sus-
pension in RPMI 1640 supplemented with B27, 20 ng/ml epi-
dermal growth factor, and 100 ng/ml Noggin (Peprotech) for 1
week. Finally, the cells were incubated in RPMI 1640 medium
with 0.5% bovine serum albumin, 10 mM nicotinamide, and 50
ng/ml insulin-like growth factor II for 5 days and without insu-
lin-like growth factor II for another 2 days (stage 4).
Glucose-stimulated Insulin Release Assay—Insulin secretion
analysiswas performed as described previously (8). Cell clusters
after stage 4 were attached to a Matrigel-coated plate and were
washed with glucose-free RPMI 1640 medium. The cells were
first incubated with RPMI 1640 medium containing 2.8 mM
glucose for 3 h, at which point the supernatant was collected.
The cells were then treated with RPMI 1640 medium contain-
ing 40 mM glucose for another 3 h. The C-peptide levels in the
supernatants were measured using the Mercodia ultrasensitive
human C-peptide enzyme-linked immunosorbent assay kit,
and the total amount of C-peptide in the supernatants was nor-
malized according to the DNA content of islet-like clusters.
RESULTS
Generation of iPS Cells from Human Foreskin Fibroblasts—
Recent studies indicate that ES-like pluripotent iPS cells can be
generated through ectopic expression of defined transcription
factors in differentiated mouse and human cells (10–14,
17–20). Although human iPS cells are capable of generating all
three germ layers in mice, whether they can differentiate into
cells of pancreatic endocrine lineages is not known. To address
this question, we attempted to generate human iPS cells by
retroviral expression of human Oct4, Sox2, Klf4, and c-Myc in
the HFF-1 human foreskin fibroblast cells. To this end, we
expressed the four transcription factors in the HFF-1 foreskin
fibroblasts by retroviral transduction. Colonies were visible 9
days after the second transduction, and about 80–100 colonies
were observed at day 16 from the initial 5  104 cells seeded in
each 10-cm plate. A total of 26 colonies, picked on days 16, 23,
and 30 after transduction, were propagated in hES cell culture
medium on primary MEFs and passaged manually every 5–6
days. From the 26 colonies picked, we successfully established
nine iPS cell lines (see below).
Characterization of Human iPS Cells—Each of the nine iPS
cell clones exhibited andmaintainedmorphology distinct from
the original human fibroblasts and resembled hES cells for at
least 14 passages in culture (Fig. 1A and supplemental Fig. S1).
The various iPS clones propagated at a similar rate but varied in
their percentage of spontaneous differentiation during culture.
To confirm that these iPS cells exhibit hES-like properties, we
examined a number of hES cell markers that include alkaline
phosphatase activity, ES cell-specific transcription factors Sox2
and Oct4, and hES cell-specific extracellular antigens TRA-
1–60 and SSEA-4. As a negative control, we also analyzed
SSEA-1, amarker for differentiation of hES cells. Results shown
in Fig. 1B and supplemental Fig. S1 demonstrate that the iPS
clones exhibit hES-like properties, including high alkaline
phosphatase (AP) activity, and positive staining for Sox2, Oct4,
TRA-1–60, and SSEA-4. Themajority of the colonieswere neg-
ative for the SSEA-1, with a few positive cells observed on the
periphery of some colonies. Staining intensity for all markers
tested was similar to that observed with the well characterized
hES cell line H9 (supplemental Fig. S1). The original HFF-1
fibroblast cell line was negative for these markers (supplemen-
tal Fig. S1).
To assess the gene expression pattern of the iPS clones, we
isolated RNA from iPS cells that were cultured under feeder-
free conditions for at least two passages. All of the selected
clones maintained the morphological characteristics observed
for hES cell lines when cultured on fibronectin or similar
matrixes (data not shown). RT-PCR analysis confirmed expres-
sion of the genes essential for hES cell maintenance, including
Nanog, Crypto, telomerase (TERT), Rex1, Dppa5, UTF1,
TERF1, TERF2, fibroblast growth factor receptor 4 (FGFR4),
and Glut1 glucose transporter. None of these genes were
expressed in the originalHFF-1 fibroblasts (Fig. 1C). Expression
FIGURE 1. iPS cells generated from human foreskin cells exhibit hES cell
characteristics. A, a phase-contrast micrograph of a representative iPS clone
showing hES-cell like morphology that is distinct from the parental human
foreskin fibroblast cell line HFF-1. B, alkaline phosphatase (AP) activity analysis
and hES cell marker staining demonstrate ES-like features of a representative
iPS clone 7. Alkaline phosphatase activity and immunostaining (red) of iPS
cells, counterstained by DAPI (blue), confirmed expression of the ES cell mark-
ers throughout the colonies. Little or no staining for SSEA-1 was observed
within the colonies confirming the undifferentiated state of the cells. C, iPS
cells express genes important for hES cell maintenance. RT-PCR analysis of the
gene expression profile of seven representative human iPS (hIPS) cell lines
demonstrates a similar expression profile to that of the hES cell line H9 but
different from their parental fibroblast HFF-1 cells. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase. D, the DNA methylation state of the Oct4 pro-
moter is reprogrammed in iPS cells. The DNA methylation state of the Oct4
promoter in the hES cell line H9, the parental fibroblast cell line HFF-1, and
two iPS cell lines was analyzed by bisulfite sequencing. Each line represents
one clone. Black, open, and gray circles represent methylated, unmethylated,
and difficult to read CG dinucleotides within the Oct4 promoter, respectively.
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of other genes such as ABCG2, Cx43, Cx45, LifaR, and gp130,
which play more general roles in cell maintenance, was main-
tained in both iPS cells and the parental fibroblasts (Fig. 1C).
RT-PCR analysis using primers that only amplify endogenous
Sox2 andOct4 genes confirmed activation of these loci (supple-
mental Fig. S2). Previous studies have established a tight con-
nection between the efficiency of somatic cell reprogram-
ming and the DNA methylation status of the Oct4 promoter
(21). We therefore analyzed the DNA methylation status of
the Oct4 promoter by bisulfite sequencing. Results shown in
Fig. 1D demonstrate that, similar to the H9 hES cells, the
promoter of Oct4 is hypomethylated in the iPS cells, which is
in stark contrast to the heavy degree of methylation observed
in the original HFF-1 fibroblasts, further supporting success-
ful reprogramming.
To confirm the multipotency of the human iPS cells, we
injected five lines of iPS cells subcutaneously or intramuscu-
larly into Rag2//gamma-C/mice. Teratomas formed 4–6
weeks after injection. H&E and immunostaining of tumor sec-
tions from teratomas dissected 6 weeks after injection demon-
strated the presence of cell types of all three germ layers (Fig.
2A), including neural and non-neural ectoderm (Fig. 2, B and
C), pigmented epithelium (Fig. 2D), smooth muscle and fat tis-
sue (mesoderm) (Fig. 2, D and E), and airway and gut-like epi-
thelial tissues (endoderm, Fig. 2F). Collectively, the above
results demonstrate that the cell lines that we generated exhibit
all the features of blastocyst-derived human ES cells and are
therefore qualified to be human iPS cells.
Differentiation of iPS Cells into Insulin-secreting Islet Clus-
ters—Having confirmed the multipotency of the iPS cells, we
asked whether they are capable of differentiating into the pan-
creatic endocrine lineage as successful generation of insulin-
secreting cells has great potential in the development of regen-
erative therapy for diabetes. To address this possibility, we
adapted a recently developed serum-free differentiation proce-
dure fromwhich hES cells have been successfully differentiated
into insulin-secreting islet-like clusters (8). Four randomly cho-
sen iPS cell lines, numbers 1, 3, 7, and 8, and the hESH9 cell line
were subjected to the four-stage differentiation procedure out-
lined in Fig. 3A. Although all four iPS cell lines express human
ES cell markers (Fig. 1, B andC, and supplemental Fig. S1), only
iPS lines 3 and 7 survived the differentiation procedures, indi-
cating that iPS lines 1 and 8 may not be truly multipotent. As
reported previously, activin A and sodium butyrate treatment
leads to considerable morphological change of hES cells (Fig.
3B, panels a and d). Similar morphological changes were also
observed for the iPS cells 3 and 7 (Fig. 3B, panels b and e and
panels c and f). After stage 2, those cells, from either hES or iPS
cells, formed cellular aggregates under low attachment condi-
tions (Fig. 3B, panels g–i). By stage 4, the aggregates became
fused to each other, and some small bud-like clusters
appeared (Fig. 3B, panels j–l, arrows). The results suggest
that iPS clones 3 and 7 undergo similar morphological
changes to those of hES cells in response to the pancreatic
cell lineage differentiation procedure.
To determine whether these morphological changes reflect
successful differentiation of both hES and iPS cells into pancre-
FIGURE 2. iPS cells generated from human foreskin cells have the poten-
tial to differentiate into the three germ layers in vivo. A, low magnification
of H&E staining of a section from a representative human iPS cell-derived
teratoma. Cells of different lineages were observed within the tumor section.
B and C, cells of ectoderm lineage, such as the neuroprogenitor rosettes and
epidermal cells suggested by H&E staining (B, arrow), were confirmed by nes-
tin (red) and cytokeratin 19 (green) staining (C). D and E, cells of mesoderm
lineage, such as the fat tissue and smooth muscle cells seen in H&E staining (D,
arrow), were confirmed by -smooth muscle actin (red) and myosin heavy
chain (green) staining (E). F, H&E staining reveals gut-like and airway epithelial
structure, representative of endoderm lineage.
FIGURE 3. iPS cells and hES cells exhibit similar morphological changes
during islet-like cluster differentiation. A, schematic representation of the
procedure for generating islet-like clusters from hES and iPS cells. bFGF, basic
fibroblast growth factor; EGF, epidermal growth factor; IGF-II, insulin-like
growth factor II; NaButyrate, sodium butyrate. B, morphological changes of
hES H9 cells and representative iPS cells during the differentiation proce-
dure. Arrows (in panels j–l) indicate the budding structure in the colonies.
Bar, 500 m.
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atic cell lineages, we analyzed the gene expression pattern of
pancreatic lineages at each stage of the differentiation process
by quantitative RT-PCR. As shown in Fig. 4A, the definitive
endoderm-specific genes, such as Foxa2 and Sox17, are
expressed at high levels after completion of stage 1. After treat-
mentwith basic fibroblast growth factor, epidermal growth fac-
tor, and noggin, expression of Pdx1, markers of pancreatic lin-
eage cells, is readily detectable. At stage 3, NKX6.1, Ptf1, and
insulin mRNAs are detectable, and insulin mRNA reaches the
highest level at stage 4. Importantly, both iPS line 3 and iPS line
7 in general exhibited similar gene expression profiles as that of
the human H9 ES cells, indicating that iPS cells and hES cells
have similar differentiation potential for endoderm pancreatic
lineage. To further confirm expression of key genes during the
differentiation process, we analyzed protein expression of
Foxa2 and Sox17 in stage 1, Pdx1 in stage 2, and C-peptide and
glucagon in stage 4 by immunostaining. Results shown in Fig.
4B demonstrate that activinA and sodiumbutyrate induced the
expression of Foxa2 and Sox17 in the nuclei of iPS cells as well
as hES cells (Fig. 4B, panels a–f). In addition, Pdx1 protein was
clearly detected in cells derived
from both hES and iPS cells after
stage 2 (Fig. 4B, panels g–i). Finally,
both C-peptide and glucagon-posi-
tive cells were detected in the cells
of stage 4 (Fig. 4B, panels j–r). Con-
sistent with a previous report (8),
the expression of pancreatic hor-
mones was predominantly localized
in the small budding clusters.
Therefore, we conclude that, similar
to hES cells, the iPS cells derived from
foreskin fibroblasts can be differenti-
ated into islet-like endocrine cells.
Next we performed a functional
test for the differentiated islet-like
clusters. To this end, we measured
insulin secretion upon glucose stim-
ulation using C-peptide enzyme-
linked immunosorbent assay. At
low glucose concentration (2.8mM),
levels of insulin secretion, as meas-
ured by the level of C-peptide, are
comparable among islet-like cells
derived from hES and iPS cells (Fig.
5A). At high glucose concentration
(40 mM), hES cell-derived islet-like
cells responded to glucose stimula-
tion (Fig. 5A) (8). Importantly, islet-
like cells derived from iPS clone 3
also responded to high glucose
stimulation by insulin secretion,
although the response from iPS
clone 7 is marginal (Fig. 5A). Previ-
ous studies indicate that long time
exposure to high concentration glu-
cose can cause apoptosis of human
islet cells (22). To exclude the possi-
bility that the increased levels of C-peptide in the supernatant
under high glucose concentrationwere caused by increased cell
death, we examined apoptosis of insulin-positive cells by
TUNEL assay. Results shown in Fig. 5B demonstrate that most
C-peptide-positive cells were TUNEL-negative, thus ruling out
the possibility that the increased release of C-peptide after high
glucose treatment is related to apoptosis. Therefore, we con-
clude that iPS cells, like hES cells, have the potential to differ-
entiate into functional islet-like clusters in vitro, although
clonal variation exists. We note that although the two iPS lines
used in our differentiation protocol exhibited no noticeable dif-
ference from the H9 hES cells in terms of marker gene expres-
sion and teratomas formation, the islet-like clusters generated
from them exhibited quantitative differences in glucose
response. It is possible that variation in transgene copy number
and/or their degree of silencing (supplemental Fig. S2) might
contribute to the observed differences. However, more exten-
sive studies are needed to determine the basis of the variation.
We note that similar variations in the differentiation potential
of different hES cell lines have been reported (23, 24).
FIGURE 4. iPS cells can be differentiated into insulin-producing islet-like clusters. A, quantitative RT-PCR
analysis of the expression of the various cell lineage markers at the different stages of differentiation. Relative
levels of gene expression were normalized to the actin mRNA level. The value of undifferentiated (Undif)
human ES cells is arbitrarily set as 1. B, immunostaining of pancreatic lineage marker proteins in hES (panels a,
d, g, j, m, and n) and iPS (panels b, c, e, f, h, i, k, l, o, p, q, and r)-derived cells. panels a–f, stained after stage 1; panels
g–i, stained after stage 2; panels j–l, C-peptide and glucagon staining after stage 4. Panels m–r, high magnifi-
cation of C-peptide and glucagon staining. Bar  500 m (panels a–l); 10 m (panels m–r).
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DISCUSSION
Recent success in generating ES cell-like pluripotent iPS cells
from somatic cells using defined factors has provided a comple-
mentary method to somatic nuclear transfer for nuclear repro-
gramming (10–13, 17–20). This technical breakthrough has
significant implications for overcoming the ethical issues asso-
ciated with hES cell derivation from human embryos. In addi-
tion, it also makes the generation of patient-specific multipo-
tent stem cells possible. Despite the fact that several safety
issues, such as oncogenic and viral integration, which has been
associated with genome instability, must be overcome before
iPS technology can be used in patients, the implication of this
technology in replacement therapy is far reaching.
Among all the diseases that can be potentially treated by cell
therapy, type I diabetes is one of the most attractive candidates
as pancreatic transplantation or islet infusion has shown great
promise in achieving independence from insulin injection
(2–4). For this reason, we tested the differentiation potential of
human iPS cells into insulin-producing ILCs.Wedemonstrated
that the iPS cells derived from human skin cells can be differ-
entiated into pancreatic ILCs. Our results provided evidence
that functional endocrine cells can be generated in vitro from
human somatic cells. Given that islet cell transplantation ther-
apy has been proven to be beneficial to patients with type I
diabetes (2, 3), generation of patient-specific iPS cells and sub-
sequent differentiation of these iPS cells into insulin-secreting
cells may prove to be a potential cell source for transplantation
therapy. However, before this approach can become practical,
several obstaclesmust be overcome. First, although the iPS cells
and human ES cells have comparable efficiency of differentia-
tion into insulin-secreting islet clusters, the general efficiency is
extremely low. In addition, the levels of C-peptide secreted by
in vitro differentiated islet-like cells from both iPS cells and
human ES cells are much lower when compared with that of
adult human -cells. The low efficiency of these two aspects is
caused by the limitation of current in vitro differential protocol
but not the intrinsic properties of the iPS cells. For this reason,
it is essential to establish efficient differentiation procedures
that significantly increase the formation of insulin-secreting
cells and their response to glucose. One approach that has
shown great promise is in vivo maturation of endocrine cells
through transplantation of in vitro differentiated pancreatic
endoderm cells (9). Second, since type I diabetes is an autoim-
mune disease, the iPS-derived insulin-producing cells can be
attacked by the autoreactive T cells. Although the immunolog-
ical problem is serious, the self-renewal capacity of iPS cells
might partially address the continuous retreatment of the dis-
ease by the availability of autologous iPS-derived cells without
sensitization by donor tissues, which is one of the major prob-
lems in repeated infusion of islets derived frommultiple donors
(25). Third, the obvious obstacles for iPS cell-based therapy that
are associated with the reprogramming process, such as the
introduction of the oncogenes and possible mutations due to
the use of integrating viral vectors, must also be overcome.
Given the amazing progress that has been made in the past 2
years, we anticipate that it will not be long before these obsta-
cles are resolved.
It is worth noting that although individual iPS cell clones
showedno significant difference in cellmorphology, expression
of pluripotent marker genes, or DNA demethylation at the
Oct4 promoter, we observed clonal variability in their potential
to differentiate into the pancreatic lineage cells. Of the four iPS
cell clones that we tested in the same differentiation procedure,
two iPS clone failed to maintain islet-like cell aggregates (data
not shown). The clonal variability in terms of differentiation
potential indicates that not all human iPS clones are fully plu-
ripotent although they passed the standard tests. This raises the
question regarding the criteria for “true” human iPS cells.
Because the differentiation protocol used in this study has
clearly defined developmental stages, we will be able to
define the specific blockage of the differentiation process for
some of the “incompletely” reprogrammed clones. This
information, in combination with other factors, such as epi-
genetic modifications and microRNA profiling, might help
us to establish the criteria for true human iPS cells with full
differentiation potential.
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FIGURE 5. The iPS-derived islet-like cluster secretes insulin upon glucose
stimulation. A, iPS-derived islet-like cluster responses to glucose-stimulated
insulin secretion. The islet-like clusters were sequentially treated with low (2.8
mM, black bar) and high (40 mM, white bar) concentrations of glucose, and the
supernatants were collected and analyzed for C-peptide concentration by
enzyme-linked immunosorbent assay. The amount of C-peptide was normal-
ized to DNA content. Data were collected in triplicate. undi-H9 and dif-H9
indicate undifferentiated H9 and H9-derived islet-like clusters, respectively.
*, p  0.05. B, TUNEL analysis of islet-like clusters derived from H9 (upper) and
iPS (lower) cells under high concentration of glucose. Green, TUNEL-positive
cells; red, C-peptide-expressing cells.
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